Evidence map›Paper›PMID 37313549›Full record

ArticleStatistics in biosciences2023

On the Methodological Aspects of the Clinical Trials for COVID-19 Conducted in the First Year of the Pandemic: A Descriptive Analysis.

Eleni Georgiadi, Athanasios Sachlas

Abstract read
In one paragraph

Article in Statistics in biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eleni GeorgiadiDepartment of Medicine, National and Kapodistrian University of Athens, Mikras Asias 75, Athens, 115 27 Greece.
Athanasios SachlasDepartment of Computer Science and Biomedical Informatics, University of Thessaly, Papasiopoulou 2-4, Lamia, 351 31 Greece.ORCID 0000-0003-0546-3162

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2020, the whole planet was plagued by the extremely deadly COVID-19 pandemic. More than 83 million people had been infected with COVID-19 while more than 1.9 million people around the planet had died from this virus in the first year of the pandemic. From the first moment, the medical community started working to deal with this pandemic. For this reason, many clinical trials have been and continue to be conducted to find a safe and efficient cure for the virus. In this paper, we review the 96 clinical trials, registered in the ClinicalTrials.gov database, that had been completed by the end of the first year of the pandemic. Although the clinical trials contained significant heterogeneity in the main methodological features (enrollment, duration, allocation, intervention model, and masking) they seemed to be conducted based on an appropriate methodological basis.

Indexed as

Clinical trialsCOVID-19Descriptive analysisPandemicRisk of biasSARS-CoV-2Statistical design

Identifiers

PMID37313549
PMCPMC10019791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.